JNJJanssen Research & Development, LLCSigning up patients
A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 230 (planned)
- Started
- Jun 30, 2026
- Main results expected
- Dec 31, 2027
- Fully finished
- Jul 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS)
Measured over: By the end of Day 28 from first ramantamig dose
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07589634 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC